These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 37855871)

  • 1. Multiple sclerosis in the elderly: a retrospective cohort study.
    Zinganell A; Göbel G; Berek K; Hofer B; Asenbaum-Nan S; Barang M; Böck K; Bsteh C; Bsteh G; Eger S; Eggers C; Fertl E; Joldic D; Khalil M; Langenscheidt D; Komposch M; Kornek B; Kraus J; Krendl R; Rauschka H; Sellner J; Auer M; Hegen H; Pauli FD; Deisenhammer F
    J Neurol; 2024 Feb; 271(2):674-687. PubMed ID: 37855871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and demographic characteristics of late-onset multiple sclerosis: LOMS-TR study.
    Sıvacı AÖ; Seferoğlu M; Piri Çınar B; Uzunköprü C; Beckmann Y; Güngör Doğan İ; Çetinkaya Tezer D; Tunç A; Ethemoğlu Ö; Gümüş H; Açıkgöz M; Yalaz Tekan Ü; Demir S
    Mult Scler Relat Disord; 2024 Apr; 84():105469. PubMed ID: 38341979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
    Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
    Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
    Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
    Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
    Jakimovski D; Kavak KS; Coyle PK; Goodman AD; Gottesman M; Zivadinov R; Weinstock-Guttman B;
    J Neurol; 2024 Feb; 271(2):711-722. PubMed ID: 37995009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
    Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
    Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Mouresan EF; Mentesidou E; Berglund A; McKay KA; Hillert J; Iacobaeus E
    Neurology; 2024 Mar; 102(6):e208051. PubMed ID: 38394472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Sclerosis Progression and Relapse Activity in Children.
    Iaffaldano P; Portaccio E; Lucisano G; Simone M; Manni A; Guerra T; Paolicelli D; Betti M; De Meo E; Pastò L; Razzolini L; Rocca MA; Ferrè L; Brescia Morra V; Patti F; Zaffaroni M; Gasperini C; De Luca G; Ferraro D; Granella F; Pozzilli C; Romano S; Gallo P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Banfi P; Lugaresi A; Totaro R; Spitaleri D; Cocco E; Di Palma F; Maimone D; Valentino P; Torri Clerici V; Protti A; Maniscalco GT; Salemi G; Pesci I; Aguglia U; Lepore V; Filippi M; Trojano M; Amato MP;
    JAMA Neurol; 2024 Jan; 81(1):50-58. PubMed ID: 38010712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns and persistence on disease modifying therapies for multiple sclerosis and its associated factors.
    Cárdenas-Robledo S; Arenas-Vargas LE; Arenas RD; Gaspar-Toro JM; Muñoz-Rosero ÁM; Tafur-Borrero AH; Marín-Medina DS; Acosta-Fajardo HA; Guío-Sánchez C; López-Reyes L
    BMC Neurol; 2024 Apr; 24(1):108. PubMed ID: 38566012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Untreated patients with multiple sclerosis: A study of French expert centers.
    Moisset X; Fouchard AA; Pereira B; Taithe F; Mathey G; Edan G; Ciron J; Brochet B; De Sèze J; Papeix C; Vermersch P; Labauge P; Defer G; Lebrun-Frenay C; Moreau T; Laplaud D; Berger E; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Créange A; Camdessanché JP; Bakchine S; Maurousset A; Hankiewicz K; Pottier C; Maubeuge N; Dimitri Boulos D; Nifle C; Vukusic S; Clavelou P;
    Eur J Neurol; 2021 Jun; 28(6):2026-2036. PubMed ID: 33650261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study.
    Guillemin F; Baumann C; Epstein J; Kerschen P; Garot T; Mathey G; Debouverie M;
    Neuroepidemiology; 2017; 48(3-4):179-187. PubMed ID: 28793296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
    Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A;
    JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapses add to permanent disability in relapsing multiple sclerosis patients.
    Koch-Henriksen N; Sørensen PS; Magyari M
    Mult Scler Relat Disord; 2021 Aug; 53():103029. PubMed ID: 34116481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression.
    Salavisa M; Serrazina F; Ladeira AF; Correia AS
    Clin Neurol Neurosurg; 2023 Feb; 225():107612. PubMed ID: 36701940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.